Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
QIFENG
873169
5
LAISAI LASER
871263
US OptionsDetailed Quotes
VRNA250516P55000
- 0.26
- -0.09-25.71%
15min DelayClose May 9 16:00 ET
0.36High0.26Low
0.36Open0.35Pre Close35 Volume5.69K Open Interest55.00Strike Price1.23KTurnover85.16%IV13.55%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type-0.0818Delta0.0226Gamma243.54Leverage Ratio-0.0859Theta-0.0008Rho-19.93Eff Leverage0.0119Vega
Verona Pharma Newsroom
A Quick Look at Today's Ratings for Verona Pharma(VRNA.US), With a Forecast Between $85 to $107
Verona Pharma Price Target Raised to $107.00/Share From $93.00 by Wells Fargo
Analysts' Opinions Are Mixed on These Healthcare Stocks: The Ensign Group (ENSG), Verona Pharma (VRNA) and Atricure (ATRC)
Analysts Offer Insights on Healthcare Companies: Option Care Health (OPCH), Incyte (INCY) and Verona Pharma (VRNA)
Verona Pharma Is Maintained at Buy by HC Wainwright & Co.
Verona Pharma Analyst Ratings
Truist Securities Adjusts Verona Pharma Price Target to $100 From $76, Maintains Buy Rating
TD Cowen Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $100
Verona Pharma's Promising Outlook: Buy Rating Backed by Strong Ohtuvayre Sales and Strategic Positioning
Verona Pharma Initiated With a Buy at TD Cowen
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $76
Analysts Conflicted on These Healthcare Names: Verona Pharma (VRNA), Neogen (NEOG) and ANI Pharmaceuticals (ANIP)
Cantor Fitzgerald Initiates Verona Pharma(VRNA.US) With Buy Rating, Announces Target Price $80
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating
Piper Sandler Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $76
BTIG Maintains Verona Pharma(VRNA.US) With Buy Rating, Maintains Target Price $83
Wells Fargo Maintains Overweight on Verona Pharma, Raises Price Target to $93
Truist Financial Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $76
Roth MKM Maintains Verona Pharma(VRNA.US) With Buy Rating, Raises Target Price to $83
A Quick Look at Today's Ratings for Verona Pharma(VRNA.US), With a Forecast Between $72 to $93
Market Insights
Discussing
Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve
Buffettttttt
May 3 21:00
Berkshire's 2025 Annual Shareholders Meeting
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
